Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion - LARVOL DELTA

As-Needed Albuterol-Budesonide in Mild Asthma. (PubMed, Pediatrics) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Albuterol-budesonide Treatment in Acute Airway Obstruction: Onset and Duration of Lung Function and Symptom Improvement (ACAAI 2025) - P3 | "Treatments showed similar adverse event rates. Conclusions Albuterol-budesonide relieves acute obstruction as-fast-as albuterol alone, providing nominally greater lung function improvement over time and rapid, sustained dyspnea relief."

Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Combination Short-Acting Bronchodilator and Inhaled Corticosteroid Rescue Therapy (the ANCHOR Study): Rationale and Design (ACAAI 2025) - "Results/Conclusions ANCHOR evaluates the changes in annualized asthma exacerbation rates after switching rescue therapy to a single albuterol plus budesonide inhaler among participants with asthma using health insurance claims data. The unique study model with minimal intervention and utilizing real-world claims data enables researchers to understand treatment patterns and drug effectiveness in the real-world setting."

Asthma • Immunology • Respiratory Diseases

Treatment for Mild Asthma: What Matters to Providers (ACAAI 2025) - "Specialists were more likely to utilize MART therapy than generalists (budesonide/formoterol: 62.5% vs. 60.0% p 0.002, mometasone/formoterol 58.5% vs. 34.8% p 0.019). Similarly, specialists were more likely to prescribe budesonide-albuterol for reliever therapy than generalists (20.1% vs. 4.5%, p<0.001), and attendings more than trainees (17.5% vs. 6.2%, p 0.025)...Lastly, specialists are more likely to utilize asthma action plans (63.5% vs. 43.4%, p 0.030). Conclusion Significant heterogeneity exists in the definition and treatment of mild asthma."

Asthma • Gynecology • Immunology • Obstetrics • Pediatrics • Respiratory Diseases

Use of As-needed Albuterol-budesonide versus Albuterol Before and After a Severe Exacerbation: BATURA Post-hoc Analysis (ACAAI 2025) - P3 | "Numerically, less ALB–BUD versus ALB was used in the two weeks before and after an exacerbation ( Figure ). Conclusion ALB–BUD versus ALB numerically reduced the overall use of rescue inhalations surrounding an exacerbation among patients with mild asthma."

Retrospective data • Asthma • Immunology • Respiratory Diseases

Albuterol–budesonide Reduces Exacerbations in Uncontrolled Mild Asthma With or Without Exacerbation History-based Risk (ACAAI 2025) - "Conclusion Patients with mild asthma and symptoms, regardless of prior-year exacerbation history, are at risk for future-year exacerbations. Albuterol–budesonide reduces exacerbation risk relative to albuterol, whether lack of control is based on IMP-only or IMP+risk."

Late-breaking abstract • Asthma • Immunology • Respiratory Diseases

In poorly controlled mild asthma, as-needed budesonide plus albuterol is more effective than albuterol alone. (PubMed, Recenti Prog Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

TUSSIVE SYNCOPE IN A PATIENT WITH INFLUENZA B AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (CHEST 2025) - "After testing positive for Influenza B, he was prescribed oseltamivir. He was advised to continue his COPD medications, including triple therapy (fluticasone, umeclidinium, vilanterol) and ipratropium/albuterol inhalers...He returned to his primary care provider 3 days later, who started him on amoxicillin-clavulanate, benzonatate, and prednisone...He was treated with budesonide and albuterol nebulizers, tiotropium/olodaterol inhaler, IV methylprednisolone, diphenhydramine plus hydrocodone, and azithromycin... Patients with influenza and comorbidities such as COPD and coronary artery disease should be assessed for signs of syncope, particularly in those with prolonged and intense coughing episodes. Additionally, patient education and close monitoring are crucial to reduce the risk of fall-related injuries."

Clinical • Cardiovascular • Chronic Cough • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Hypertension • Hypotension • Immunology • Infectious Disease • Influenza • Musculoskeletal Diseases • Obstructive Sleep Apnea • Orthopedics • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

As-Needed Albuterol-Budesonide in Mild Asthma. (PubMed, N Engl J Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

As-Needed Albuterol-Budesonide in Mild Asthma. Reply. (PubMed, N Engl J Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

ALBUTEROL-BUDESONIDE COMBINATION THERAPY IN ASTHMA: A SYSTEMATIC REVIEW (CHEST 2025) - "Albuterol-budesonide combination therapy significantly improves asthma control compared to albuterol alone, as evidenced by enhanced ACQ responses in the reviewed trials. CLINICAL IMPLICATIONS: This dual-action approach offers rapid symptom relief along with sustained anti-inflammatory benefits, suggesting that it may be a valuable option for patients with moderate to severe asthma who require both immediate and long-term control."

Combination therapy • Review • Asthma • Immunology • Respiratory Diseases

AS-NEEDED ALBUTEROL-BUDESONIDE VS AS-NEEDED ALBUTEROL DECREASES SEVERE EXACERBATION RISK AND IMPROVES ASTHMA CONTROL AT 16 WEEKS IN MILD ASTHMA: BATURA POST-HOC ANALYSES (CHEST 2025) - P3 | "Sixteen weeks of as-needed albuterol-budesonide reduced severe exacerbation risk and improved asthma control versus as-needed albuterol in patients >12 years with mild asthma. CLINICAL IMPLICATIONS: BATURA in mild asthma and MANDALA in moderate-to-severe disease demonstrated sever exacerbation risk reduction as early as 16 and 12 weeks, respectively. Patients across the severity spectrum switching from albuterol to albuterol-budesonide rescue therapy can anticipate early reductions in exacerbation risk."

Retrospective data • Asthma • Immunology • Respiratory Diseases

ASTHMA CONTROL IN PARTICIPANTS WITH MILD ASTHMA ENROLLED IN THE BATURA CLINICAL TRIAL: IMPAIRMENT AND RISK PROFILES AT RANDOMIZATION (CHEST 2025) - P3 | "Uncontrolled patients treated for mild asthma have a heavy symptom burden impacting their daily lives despite most not experiencing prior-year exacerbations. CLINICAL IMPLICATIONS: Clinicians should recognize that uncontrolled patients treated for mild asthma who have not experienced prior-year exacerbations may be at risk of future exacerbations and, as demonstrated in BATURA, can benefit from a switch from SABA-only to albuterol–budesonide anti-inflammatory rescue therapy."

Clinical • Asthma • Immunology • Respiratory Diseases

DARWIN: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2025 ➔ Feb 2026 | Trial primary completion date: Nov 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Spontaneous Unilateral Epistaxis and Telangiectasia presenting similarly to Hereditary Hemorrhagic Telangiectasia (AAO-HNSF 2025) - "His medications included albuterol, budesonide-formoterol, aspirin, amlodipine, rosuvastatin, and omeprazole. This case underscores the challenges of diagnosing HHT-like conditions when genetic testing fails to identify known pathogenic variants. The findings highlight limitations in current genetic testing for distinguishing HHT from mimicking conditions or atypical cases. Investigation into other cases of unilateral epistaxis and telangiectasias is warranted to enhance diagnostic clarity and improve management strategies."

Anemia • Cardiovascular • CNS Disorders • Coronary Artery Disease • Hematological Disorders • Immunology • Vascular Neurology • ACVRL1 • SMAD4

Inhaler-Related Greenhouse Gas Emissions in the US: A Serial Cross-Sectional Analysis. (PubMed, JAMA) - "Albuterol, budesonide-formoterol, and fluticasone propionate inhalers accounted for 87% of total emissions...Inhaler-related emissions in the US have increased over the past decade. Policymakers and regulators seeking to reduce emissions should identify targeted solutions aimed at shifting utilization to currently marketed dry powder and soft mist inhalers while facilitating the entry of newer, affordable metered-dose products containing propellants with low global warming potential."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

As-needed albuterol and budesonide combined therapy is safe and effective for mild asthma. (PubMed, Am J Nurs) - "ACCORDING TO THIS STUDY."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

AIRSUPRA (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol (AstraZeneca Press Release) - "The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for AIRSUPRA....AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma."

FDA approval • Asthma • Immunology

Albuterol-budesonide rescue inhaler for asthma: patterns of use and safety in the MANDALA trial. (PubMed, Ann Allergy Asthma Immunol) - P3 | "Patterns of use and safety profiles were similar between as-needed albuterol-budesonide and albuterol."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of three treatment strategies in mild asthma: A carbon-utility analysis. (PubMed, J Allergy Clin Immunol Pract) - "We applied to the asthma field a novel methodological approach to consider both the environmental impact and effectiveness of interventions. These findings indicate that as-needed budesonide/formoterol DPI is the preferred option when considering both carbon emissions and treatment effectiveness."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Participants as Partners in Decentralized Clinical Trials. (PubMed, NEJM Evid) - "This article highlights technical and procedural considerations needed to support DCTs and identifies areas for trial innovation. By making DCTs and technology platforms participant centric and continuing to advance opportunities for innovation, researchers may accelerate scientific discovery, help participants feel their contributions are meaningful, and foster long-term trust in the biomedical research process.See also in NEJM: As-Needed Albuterol-Budesonide in Mild Asthma See also in NEJM: Your Combination Asthma Inhaler - Don't Leave Home without It!"

Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Estimating the Greenhouse Gas Emissions of Outpatient Inhalers at Stanford Medicine (ATS 2025) - "The three most prescribed inhalers were albuterol sulfate, budesonide-formoterol, and fluticasone propionate; these metered-dose inhalers alone accounted for 92% of inhaler prescriptions and 90% of inhaler-related emissions over the study period. Metered-dose inhalers accounted for the majority of inhaler prescription orders and nearly all of the inhaler-related greenhouse gas emissions from selected Stanford Medicine outpatient clinics. The carbon equivalent emissions associated with metered-dose inhaler prescriptions at these clinics were equivalent to driving an average gasoline-powered passenger vehicle for 335,218 miles. While the increased use of propellant-free dry powder and soft mist inhalers may reduce the carbon footprint of respiratory care, individual prescribing decisions must be weighed against clinical and cost considerations."

Clinical • Immunology

Efficacy of As-needed Albuterol‒Budesonide Versus Albuterol on Systemic Corticosteroid Exposure in Participants With Mild Asthma: BATURA Prespecified Analysis (ATS 2025) - P3 | "Here, we report the difference in total SCS exposure between treatment groups in prednisone equivalents. Total SCS exposure for the overall population was 2.7-fold greater in the ALB group compared to the ALB-BUD group (Figure). Conclusions In participants with mild asthma in the BATURA trial, rescue therapy with as-needed ALB-BUD reduced the total SCS exposure compared with ALB, reducing known risks from cumulative exposure to SCS."

Clinical • Asthma • Immunology • Respiratory Diseases

Can a New Portable Valved Holding Chamber (VHC) for Use on the Go Improve the Delivery and Reduce Side Effects of a New Combination Albuterol/Budesonide Inhaler? (ATS 2025) - "This study showed that the AeroChamber2go[asterisk] and AeroChamber Plus[asterisk] Flow-Vu[asterisk] VHCs provided similar FPM, compared to the MDI alone. Additionally, the VHCs reduced the CPM associated with oropharyngeal deposition, which could be particularly important with inhaled corticosteroids like budesonide. If deposited in the oropharyngeal region, absorption into the bloodstream increases the potential for systemic side effects."

Adverse events • Asthma • Immunology • Respiratory Diseases

Baseline Characteristics of Patients With Asthma Initiating Albuterol-Budesonide Rescue: A Real-world US Claims-based Study (ATS 2025) - "Conclusions Among early adopters of albuterol−budesonide as a rescue therapy in the United States, patients commonly presented with substantial comorbidities and a high clinical burden. The treatment has been initiated across the spectrum of asthma severity and control levels, as established with previous clinical evidence."

Clinical • Real-world • Real-world evidence • Allergic Rhinitis • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases